SCHEMBL2183528

SCHEMBL2183528

CC1[C]c2ccccc2CC1

nearest known ligand 0.37

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
PDPK1 O15530 1/20 0.37
PLAU P00749 1/20 0.36
ACHE P22303 1/20 0.34
DRD2 P14416 2/20 0.33
IDO1 P14902 1/20 0.33
MAOA P21397 1/20 0.33
MAOB P27338 1/20 0.33
DRD1 P21728 1/20 0.33
DRD4 P21917 1/20 0.33
DRD5 P21918 1/20 0.33
DRD3 P35462 1/20 0.33
MTNR1A P48039 1/20 0.33
MTNR1B P49286 1/20 0.33
TSHR P16473 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11004524 0.78 ACHE (0.41) ACHEIDO1MAOAMAOBDRD3
SCHEMBL3653495 0.75 PLAU (0.41) PDPK1PLAUIDO1TSHR
SCHEMBL1383876 0.75 ANPEP (0.39) PDPK1PLAUIDO1MTNR1AMTNR1B
SCHEMBL10390219 0.75 HTR1A (0.37) PDPK1PLAUDRD2MAOAMAOB
SCHEMBL9067653 0.75 HTR1A (0.37) PDPK1PLAUDRD2MAOAMAOB
SCHEMBL5714371 0.75 PRCP (0.36) PDPK1PLAUDRD2IDO1MTNR1A
SCHEMBL1634692 0.72 CYP11B2 (0.41) PLAUMAOAMAOBMTNR1AMTNR1B
SCHEMBL10390238 0.72 HTR1A (0.38) PDPK1DRD2MTNR1AMTNR1B
SCHEMBL4769652 0.71 PNMT (0.37) PDPK1PLAUIDO1MTNR1AMTNR1B
SCHEMBL7980704 0.69 PRCP (0.39) PDPK1PLAUTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113234194-B Copolymer, primer composition, double-layer system and application of double-layer system in double-layer stripping process 北京科华微电子材料有限公司 2022-08-12 CN claimed
CN-113234194-A Copolymer, primer composition, double-layer system and application of double-layer system in double-layer stripping process 北京科华微电子材料有限公司 2021-08-10 CN claimed
JP-2010535193-A 2010-11-18 JP claimed
US-20100137258-A1 THIOPHOSPHI(O)NIC ACID DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) 2010-06-03 US claimed
EP-2183258-A2 THIOPHOSPHI(O)NIC ACID DERIVATIVES AND THEIR USE AS AGONISTS OR ANTAGONISTS FOR METABOTROPIC GLUTAMATE RECEPTORS Centre National de la Recherche Scientifique (CNRS) (FR) 2010-05-12 EP claimed
US-20090170813-A1 Hypophosphorous Acid Derivatives and their Therapeutical Applications CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.) (FR) 2009-07-02 US claimed
JP-2009511624-A 2009-03-19 JP claimed
WO-2009016520-A2 THIOPHOSPHI(O)NIC ACID DERIVATIVES AND THEIR USE AS AGONISTS OR ANTAGONISTS FOR METABOTROPIC GLUTAMATE RECEPTORS CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) 2009-02-05 WO claimed
EP-1937699-A2 HYPOPHOSPHOROUS ACID DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) 2008-07-02 EP claimed
WO-2007135417-A1 BENZOTRIAZEPINONE DERIVATIVES JAMES BLACK FOUNDATION (GB) 2007-11-29 WO claimed
WO-2007135350-A1 BENZOTRIAZEPINONE DERIVATIVES JAMES BLACK FOUNDATION (GB) 2007-11-29 WO claimed
WO-2007052169-A2 HYPOPHOSPHOROUS ACID DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) 2007-05-10 WO claimed
WO-2006129120-A9 BENZOTRIAZEPINONE DERIVATIVES JAMES BLACK FOUNDATION (GB) 2007-03-22 WO claimed
WO-2006129120-A2 BENZOTRIAZEPINONE DERIVATIVES JAMES BLACK FOUNDATION (GB) 2006-12-07 WO claimed
US-5506262-A ANTICHOLESTEROL AGENTS, FUNGICIDES, ANTICARCINOGENIC AGENTS MERCK & CO., INC. (US) 1996-04-09 US claimed
CN-113234194-B Copolymer, primer composition, double-layer system and application of double-layer system in double-layer stripping process 北京科华微电子材料有限公司 2022-08-12 CN disclosed
CN-113234194-A Copolymer, primer composition, double-layer system and application of double-layer system in double-layer stripping process 北京科华微电子材料有限公司 2021-08-10 CN disclosed
EP-0314852-B1 Process for the preparation of 1-substituted imidazole-carbonic acid and derivatives CIBA GEIGY AG (CH) 1993-11-18 EP disclosed
US-4921955-A Process for the synthesis of 1-substituted imidazole-5-carboxylic acids and carboxylic acid derivatives CIBA-GEIGY CORPORATION (US) 1990-05-01 US disclosed
EP-0314852-A2 Process for the preparation of 1-substituted imidazole-carbonic acid and derivatives CIBA-GEIGY AG (CH) 1989-05-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137258-A1 THIOPHOSPHI(O)NIC ACID DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS C1R, TLR9, CBR1 PDPK1 4006/4885PLAU 4488/4885ACHE 3492/4885
US-20090170813-A1 Hypophosphorous Acid Derivatives and their Therapeutical Applications P4HA1, CYP2R1, EGLN3 PDPK1 4096/4885PLAU 2132/4885ACHE 4798/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.